# Handoff Report — reviewer_m4_2

**Author:** Reviewer 2 (Independent Protocol Design & Budget Reviewer)  
**Working Directory:** `C:\vazus\.agents\reviewer_m4_2`  
**Target File:** `C:\vazus\.agents\orchestrator\M3_actionable_protocol.md`  
**Date:** July 23, 2026  
**Status:** Peer Review Complete (`NEEDS_REVISION`)

---

## 1. Observation

Direct observations and quotes from `C:\vazus\.agents\orchestrator\M3_actionable_protocol.md`:

1. **Chronobiological Split (Section 1.1, Lines 71-79)**:
   - Evening Stack includes: `"Omega-3 Fatty Acids | Re-esterified Triglyceride (rTG) Liquid or Softgel | 2,000 – 3,000 mg total (1,200–1,800 mg EPA+DHA)"`.
2. **Itemized Cost Table (Section 3.1, Lines 268-276)**:
   - Item A: Combined D3 (5,000 IU) + K2 MK-7 (100 mcg) Droplets/Caps: $6.50 / month
   - Item B: Balanced Zn (15mg) + Cu (1.5mg) + Boron (6mg) + Se Matrix: $10.50 / month
   - Item C: Bulk Magnesium Bisglycinate/Malate Powder (1 kg tub): $9.00 / month
   - Item D: Bulk Micronized Creatine Monohydrate Powder (1 kg tub): $7.00 / month
   - Item E: Active B-Complex (2-Month Supply Bottled): $6.00 / month
   - Total Monthly Expenditure: `$39.00 / month (Range: $25.00 – $45.00/mo)`.
   - **Observation**: Omega-3 rTG is omitted from the Item A–E table, yet high-quality rTG Omega-3 costs $20.00–$35.00/month. Including it raises the actual stack cost to $59.00–$74.00/month.
3. **Renal Biomarker Specification (Section 5.1, Line 443)**:
   - Comprehensive Metabolic Panel (CMP): `"ALT/AST between 15 and 25 U/L, eGFR > 90 mL/min/1.73m²"`.
   - **Observation**: The protocol prescribes $5\text{ g/day}$ Creatine Monohydrate (Section 1.1, Line 66; Section 2.4, Line 222), but does not specify Cystatin C for eGFR testing. Daily oral creatine elevates serum creatinine via non-enzymatic conversion, causing false depression of creatinine-derived eGFR equations.
4. **Hydration & Electrolyte Protocol (Section 4.4, Lines 390-394)**:
   - Lists target Sodium ($3,000\text{--}5,000\ \text{mg}$), Potassium ($2,000\text{--}3,000\ \text{mg}$), and Magnesium ($400\text{--}600\ \text{mg}$).
   - **Observation**: Lacks explicit caution against dry bolus potassium powder supplementation, which poses risks of cardiac dysrhythmias and upper GI tract mucosal ulcers.
5. **Verifier Tool Command Execution**:
   - `subagent_verifier_bridge.py` was executed on `M3_actionable_protocol.md` (Task ID `task-21`). Verification logged SMT Z3 status UNSAT (depth 10), confirm AST structure parsing.

---

## 2. Logic Chain

1. **Observation 1 & 2 -> Financial Gap**: The protocol sets a clear target budget of $25–$45/month to capture 85-90% ROI. In Section 1.1, rTG Omega-3 is part of the standard Evening Stack. In Section 3.1, Items A through E sum to $39.00/month, leaving no budget allocation for rTG Omega-3 ($20–$35/month). Therefore, the current cost model either contains an itemized accounting omission or overpromises on the $25–$45 target while including rTG Omega-3.
2. **Observation 3 -> Diagnostic False Positive Risk**: Creatine monohydrate supplementation at 5g/day elevates serum creatinine levels without altering true renal glomerular filtration. Using standard creatinine-based eGFR equations (e.g. CKD-EPI creatinine) will falsely flag patients with eGFR < 90 mL/min/1.73m², leading to unnecessary clinical panic or inappropriate discontinuation of creatine. Therefore, Cystatin C (a serum marker independent of muscle mass and dietary creatine) must be specified for accurate eGFR assessment.
3. **Observation 4 -> Patient Safety Guardrail**: Rapid ingestion of concentrated potassium salts can cause acute hyperkalemia and focal esophageal/gastric ulceration. Specifying dietary potassium sources (avocado, potato, spinach, coconut water) and diluted electrolytes mitigates this safety risk.
4. **Conclusion**: M3_actionable_protocol.md is exceptionally high quality in its biochemical and chronobiological foundation, but requires minor accounting reconciliation and diagnostic safety additions (`NEEDS_REVISION`).

---

## 3. Caveats

- **Market Pricing Variations**: Bulk powder pricing (e.g., Creatine Monohydrate and Magnesium Glycinate) can fluctuate based on global raw material supply chains and shipping costs. The calculated monthly costs are based on 2026 standard market prices for 1 kg bulk containers.
- **Individual Pharmacokinetics**: Inter-individual variability in intestinal absorption (e.g., PEPT1, TRPV6, DMT-1 transporters) or genetic polymorphisms (e.g., MTHFR, MTRR, CYP24A1) may necessitate minor dose adjustments outside the standard reference ranges.
- **Dietary Baseline**: Assumptions regarding dietary potassium and selenium intake assume a standard whole-food male diet. Regional soil selenium depletion may alter baseline requirements.

---

## 4. Conclusion

- **Verdict**: **NEEDS_REVISION**
- **Rationale**: The protocol is biochemically superior and structurally thorough, but contains:
  1. An itemized accounting omission of rTG Omega-3 in Section 3.1 ($39/mo claimed vs. $59–$74/mo actual with rTG Omega-3).
  2. A missing Cystatin C diagnostic rule for creatine users in Section 5.1/5.2.
  3. A missing potassium oral safety warning in Section 4.4.
- **Actionable Next Step**: Orchestrator should update `M3_actionable_protocol.md` with these three minor additions to achieve full protocol approval.

---

## 5. Verification Method

To independently verify the review findings:

1. **Verify Financial Discrepancy**:
   - Inspect `C:\vazus\.agents\orchestrator\M3_actionable_protocol.md`, lines 77-79 (Section 1.1) vs. lines 268-276 (Section 3.1).
   - Sum Items A–E in Section 3.1 ($6.50 + $10.50 + $9.00 + $7.00 + $6.00 = $39.00). Confirm Omega-3 rTG is absent from the table while present in Section 1.1.
2. **Verify Creatine / eGFR Diagnostic Interaction**:
   - Check medical literature (e.g., Tang et al., *Kidney International*; Baxmann et al., *CJASN*) confirming that 5g daily creatine monohydrate elevates serum creatinine by 0.1–0.3 mg/dL, falsely depressing serum creatinine-based eGFR equations while Cystatin C remains unchanged.
3. **Verify Report Generation**:
   - Confirm existence and completeness of `C:\vazus\.agents\reviewer_m4_2\review_report.md` and `C:\vazus\.agents\reviewer_m4_2\handoff.md`.
